Ligand-induced expression of peroxisome proliferator-activated receptor α and activation of fatty acid oxidation enzymes in fatty liver

European Journal of Clinical Investigation

Volumn 34, Issue 6, 2004, Pages 429-435

  Akbiyik, F ^a   Cinar, K ^b   Demirpence, E ^a   Ozsullu, T ^a   Tunca, R ^b,c   Haziroglu, R ^b,c   Yurdaydin, C ^b   Uzunalimoglu, O ^b   Bozkaya, H ^b  

^a HACETTEPE UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

^c Faculty of Veterinary   (Turkey)

Author keywords

Fatty liver; Mitochondrial oxidation; Oxidative injury; Peroxisomal oxidation; PPAR

Indexed keywords

ACYL COENZYME A DEHYDROGENASE; ACYL COENZYME A OXIDASE; CATALASE; CLOFIBRATE; GLUTATHIONE; LIGAND; MALONALDEHYDE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; FATTY ACID OXIDATION; FATTY LIVER; FEEDING; IMMUNOHISTOCHEMISTRY; LIPID DIET; LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPECTROPHOTOMETRY;

ACYL-COA DEHYDROGENASE; ANIMALS; ANTILIPEMIC AGENTS; ANTIOXIDANTS; BODY WEIGHT; CLOFIBRATE; DIETARY FATS; FATTY LIVER; HEPATOCYTES; LIGANDS; LIPID PEROXIDATION; OXIDOREDUCTASES; RATS; RATS, WISTAR; RECEPTORS, CYTOPLASMIC AND NUCLEAR; TRANSCRIPTION FACTORS;

EID: 3042791281     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2004.01359.x     Document Type: Article

References (35)

1. Daynes RA, Jones DJ. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002;2:748-59.
2. Berger J, Moler DE. The mechanism of action of PPARs. Annu Rev Med 2002;53:409-35.
3. Wahli W. Peroxisome proliferator-activated receptors (PPARs): from metabolic control to epidermal wound healing. Swiss Med Wkly 2002;132:83-91.
4. Kliewer SA, Xu HE, Lambert MH, Willson TM. Peroxisome proliferator-activated receptors: from genes to physiology. Recent Prog Horm Res 2001;56:239-63.
5. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc Natl Acad Sci USA 1997;94:4312-7.
6. Hashimoto T, Fujita T, Usuda N, Cook W, Qi C, Peters JM et al. Peroxisomal and mitochondrial fatty acid β-oxidation in mice nullizygous for both peroxisome proliferator-activated receptor a and peroxisomal fatty acyl-CoA oxidase. J Biol Chem 1999;274:19228-36.
7. Younossi Z, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: An agenda for clinical research. Hepatology 2002;35:746-52.
8. Reddy JK. Nonalcoholic steatosis and steatohepatitis III. Peroxisomal β-oxidation, PPARα and steatohepatitis. Am J Physiol Gastrointest Liver Physiol 2001;281:1333-9.
9. Letteron P, Fromenty B, Terris B, Degott C, Pessayre D. Acute and chronic hepatic steatosis lead to in vivo lipid peroxidation in mice. J Hepatol 1996;24:200-8.
10. Lee SS, Pineau T, Drago J, Lee EJ, Owens JW, Kroetz DL et al. Targeted disruption of the alpha isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators. Mol Cell Biol 1995;15:3012-22.
11. Fan CY, Pan J, Usuda N, Yeldandi AV, Rao MS, Reddy JK. Steatohepatitis, spontaneous peroxisome proliferation and liver tumors in mice lacking peroxisomal fatty acyl-CoA oxidase. J Biol Chem 1998;273:15639-45.
12. Sanyal AJ, Campbell-Sargent C, Mirshahi F, Rizzo WB, Contos MJ, Sterling RK et al. Nonalcoholic steatohepatitis: Association of insulin resistance and mitochondrial abnormalities. Gastroenterology 2001;120:1183-92.
13. Green S. Peroxisome proliferators: a model for receptor mediated carcinogenesis. Cancer Surv 1992;14:222-32.
14. Rao MS, Reddy JK. Peroxisomal β-oxidation and steatohepatitis. Semin Liver Dis 2001;21:43-55.
15. Guvenc T, Haligur M, Orman MN, Haziroglu R. Mitosis and apoptosis in canine cutaneous histiocytoma and transmissible venereal tumour. Acta Vet Hungarica 2002;50:315-21.
16. Schenkman JB, Cinti DL. Preparation of microsomes with calcium. Meth Enzymol 1978;52:83-9.
17. Lazarow PB. Assays of peroxisomal β-oxidation of fatty acids. Meth Enzymol 1981;72:315-9.
18. Mihara M, Uchiyama M. Determination of malonaldehyde precursor in tissues by thiobarbituric acid test. Anal Biochem 1977;86:271-8.
19. Tietz F. Enzymic method of quantitative determination of nanogram amounts of total and oxidized glutathion: applications to mammalian blood and other tissues. Anal Biochem 1969;27:502-22.
20. Aebi H. Catalase in vitro. Meth Enzymol 1984;105:121-6.
21. Kingsley GR. The direct biuret method for the determination of serum proteins as applied to photoelectric and visual colorimetry. J Lab Clin Med 1942;27:840-5.
22. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995;270:23975-83.
23. Krey G, Braissant O, L'Horset F, Kalkhoven E, Perroud M, Parker MGW et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by co-activator-dependent receptor ligand assay. Mol Endocrinol 1997;11:779-91.
24. Mital A, Vats RK, Ramachandran U. PPARs: Nuclear receptors for antidiabetics. CRIPS 2002;3:5-8.
25. Kliewer SA, Sundseth SS, Jones SA, Brown PJ, Wisely GB, Koble CS et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ. Proc Natl Acad Sci USA 1997;94:4318-23.
26. Green S. PPAR: a mediator of peroxisome proliferator action. Mutant Res 1995;333:101-9.
27. Akbiyik F, Ray DM, Bozkaya H, Demirpence E. Ligand- and species-dependent activation of PPARα. Cell Physiol Biochem 2004, in press.
28. Choudhury AI, Chahal S, Bell AR, Tomlinson SR, Roberts RA, Salter AM et al. Species differences in peroxisome proliferation mechanisms and relevance. Mut Res 2000;448:201-12.
29. Mukherjee R, Jow L, Noonan D, McDonnell DP. Human and rat peroxisome proliferator activated receptors (PPARs) demonstrate similar tissue distribution but different responsiveness to PPAR activators. J Steroid Biochem Mol Biol 1994;51:157-66.
30. Lawrence JW, Li Y, Chen S, DeLuca JG, Berger JP, Umbenhauer DR et al. Differential regulation in human versus rodent hepatocytes by peroxisome proliferator-activated receptor (PPAR) α. J Biol Chem 2001;276:31521-7.
31. Mehendale HM. PPARα: a key to the mechanism of hepatoprotection by clofibrate. Toxicol Sci 2000;57:187-90.
32. Vega RB, Huss JM, Kelly DP. The coactivator PGC-1 cooperates with peroxisome proliferator-activated receptor α in transcriptional control of nuclear genes encoding mitochondrial fatty acid oxidation enzymes. Mol Cell Biol 2000;20:1868-76.
33. Mukherjee R, Sun RS, Santomenna L, Miao B, Walton H, Liao B et al. Ligand and coactivator recruitment preferences of peroxisome proliferator-activated receptor α. J Steroid Biochem Molec Biol 2002;81:217-25.
34. Duplus E, Glorian M, Forest C. Fatty acid regulation of gene transcription. J Biol Chem 2000;275:30749-52.
35. Costet P, Legendre C, More J, Edgar A, Galtier P, Pineau T. Peroxisome proliferator-activated receptor α isoform deficiency leads to progressive dyslipidemia with sexually dimorphic obesity and steatosis. J Biol Chem 1998;273:29577-85.